PARP1 and breast cancer: Telli and colleagues recently presented a study evaluating gemcitabine, carboplatin, and iniparib, a compound initially believed to have PARP inhibitory effects, in the neoadjuvant treatment of triple negative and BRCA-mutated breast cancer (32).